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Case Report
Anti-neutrophil Cytoplasmic Antibody-associated
Pauci-immune Crescentic Glomerulonephritis
Complicating Sjögren’s Syndrome
Wei-Jei Wang,1 Hau-Shin Wu,1 Tzong-Shinn Chu2*
Sjögren’s syndrome is a chronic autoimmune disease, characterized by specific autoimmune antibodies
anti-Ro and anti-La, and it can involve multiple organs, such as the kidneys, lungs, muscles, and nervous
system. The most common renal complication of Sjögren’s syndrome is tubulointerstitial nephritis, and
glomerulonephritis is relatively uncommon. We report the case of an 86-year-old man presenting with re-
current fever, poor appetite, decreased salivary secretion, and body weight loss. Laboratory investigation
revealed that serum creatinine was 4.2 mg/dL, proteinuria was 3+, and there was microscopic hematuria.
Positive perinuclear anti-neutrophil cytoplasmic antibody, anti-Ro, and anti-La antibodies were detected.
Renal biopsy showed crescentic glomerulonephritis with scanty immune complex deposition. The patient
was diagnosed with primary Sjögren’s syndrome complicated with rapidly progressive glomerulonephritis
with positive anti-neutrophil cytoplasmic antibody. Unlike the patients of other case reports, our patient’s
renal function did not recover after immunosuppressant treatment, and he finally received long-term 
hemodialysis. Pauci-immune glomerulonephritis is a rare renal complication of Sjögren’s syndrome, and
progress to renal failure in such patients is possible.
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Sjögren’s syndrome (SS) is a chronic autoim-
mune disease in which the exocrine glands are
attacked and infiltrated by lymphocytes, thus
causing xerostomia and xerophthalmia. Other
regions, such as musculoskeletal, pulmonary,
vascular, renal, dermatological, and neurological
systems, can also be involved in patients with
Sjögren’s syndrome. The specific autoantibodies
to Sjögren’s syndrome in diagnostic criteria revised
in 20021 are anti-Ro and anti-La, but some atypi-
cal autoantibodies, such as anti-DNA antibodies,
anti-Smith antibodies, and anti-neutrophil cyto-
plasmic antibodies (ANCA), can also be found.
We present the case of a patient diagnosed with
Sjögren’s syndrome with pauci-immune crescen-
tic glomerulonephritis, characterized by positive
perinuclear ANCA (p-ANCA), and review the 
literature.
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Case Report
An 86-year-old Taiwanese man presented to our
hospital for recurrent fever, poor appetite, de-
creased salivary secretion, and body weight loss.
He had a history of a cerebrovascular accident with
left hemiplegia for more than 10 years. He did not
previously have diabetes mellitus, renal insuffi-
ciency or hypertension, and his baseline creati-
nine (Cre) level was 1.2 mg/dL 3 months prior to
the current event. On physical examination, his
blood pressure was 122/68 mmHg and he had
coarse breath sounds bilaterally without rhonchi
or wheezing. He had no oral ulcers, lymphadeno-
pathy, or skin rash, but skin turgor was decreased.
Laboratory investigation revealed the following:
serum Cre, 4.2 mg/dL; blood urea nitrogen, 56 mg/
dL; serum potassium, 5.2 mmol/L; and hemo-
globin, 9.1 g/dL. A urinary study showed 3+ pro-
teinuria, a daily urine protein loss of 1.31 g and
microscopic hematuria (red blood cells: 25–50/
high power field) without cast or crystals. A renal
sonogram showed that the right kidney was 9.6 cm
and the left kidney was 10.7 cm in size, as well as
renal parenchymal disease with a left renal stone.
Because of the clinical suspicion of rapidly pro-
gressive glomerulonephritis, the autoimmune pro-
file was further investigated. The complement 
3 level was 92 mg/dL, complement 4 level was
22 mg/dL, and anti-double strand DNA antibody
and rheumatoid factor were both negative. How-
ever, high titers of antinuclear antibody (ANA =
1280×), positive p-ANCA (anti-myeloperoxidase,
anti-MPO, >20×), anti-Ro (65U/mL, normal range
< 10 U/mL), and anti-La (74 Ul/mL, normal range
< 10 U/mL) antibodies were detected. Shirmer’s
test was positive and a lip biopsy showed increased
lymphocyte infiltration with gland atrophy (Figure
1), compatible with Sjögren’s syndrome. In a renal
biopsy, glomeruli showed a change in crescents
without deposits (Figure 2). The interstitium
showed chronic inflammation and fibrosis, focal
tubulitis and moderate tubular atrophy. Arterioles
showed atherosclerosis without vasculitis. Pauci-
immune crescentic glomerulonephritis was con-
firmed. The patient received cyclophosphamide
pulse therapy (7 mg/kg) with oral prednisolone
20 mg per day, and 1 month later, a second cy-
clophosphamide therapy of the same dose plus
intravenous methylprednisolone 600 mg was per-
formed. However, severe sepsis occurred during
the second treatment course and his renal function
progressed to anuria with a Cre of 4.7 mg/dL.
After recovery from the episode of infectious com-
plications, the family declined further immuno-
suppressive treatment, including plasmapheresis,
and he started hemodialysis 5 months after the
initial presentation.
Discussion
ANCAs are autoantibodies against antigens in cy-
toplasmic granules of neutrophils and monocytes,
Figure 1. A large amount of lymphocytes are infiltrated over
the small salivary gland with gland atrophy (hematoxylin-
eosin stain, 200×).
Figure 2. A glomerulus is shown with crescentic change
and fibrosis. The interstitium is infiltrated with lymphocytes
(hematoxylin-eosin stain, 200×).
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classified as perinuclear (p-ANCA), cytoplasmic
(c-ANCA), and an atypical pattern. There are a
multitude of antigens recognized by p-ANCA, in-
cluding MPO, lactoferrin, elastase, and cathepsin
G, and there are many conditions associated with
the presence of ANCA, such as connective tissue
disorders (e.g. systemic lupus erythematosus and
systemic vasculitis), gastrointestinal disorders (e.g.
inflammatory bowel disease and autoimmune
hepatitis), infections, neoplasia, and drugs.2 It is
difficult to differentiate the target antigens in var-
ious clinical conditions by immunofluorescence
alone. However, MPO is recognized as the only
one of clinical significance among p-ANCAs, spe-
cific to ANCA-associated vasculitides (AAV), after
the advent of the enzyme-linked immunosorbent
assay.3 Most of the p-ANCAs present in diseases
other than AAV are those besides MPO, and their
clinical significance is still unclear.
The presence of ANCA in patients with Sjögren’s
syndrome is uncommon. Ramos-Casals et al sur-
veyed atypical autoantibodies in 402 patients with
primary Sjögren’s syndrome,4 and only 13 patients
(3.2%) presented with positive ANCA. The pres-
ence of p-ANCA was detected in 12 of the pa-
tients, and only one patient presented with atypical
ANCA. Five of the 13 patients presented with anti-
MPO antibodies, but anti-proteinase 3 antibody
was not detected. Such discriminating results are
comparable with another study. Nishiya et al fol-
lowed 60 primary Sjogren’s syndrome patients,5
and 10 patients (16.7%) presented with positive
ANCA, and all were p-ANCA. Four of them pre-
sented with anti-MPO antibody. Our case also
presented with anti-MPO antibody of p-ANCA,
but c-ANCA was not detected. In previous stud-
ies of ANCA-positive primary Sjögren’s syndrome
patients, a higher prevalence of extra-glandular
manifestations, such as pulmonary, renal, vascu-
lar, and neurological involvement, was noted in
this subgroup of patients. However, there was
less incidence of ANCA-related vasculitis, and the
probability of evolving to microscopic polyangiitis
was small. In the study by Ramos-Casals et al,4 only
one patient evolved to microscopic polyangiitis
after being followed up for more than 7 years.
Renal involvement in primary Sjögren’s syn-
drome, which is approximately 20–30%, may be
overt or latent and consists primarily of tubulo-
interstitial nephritis with interstitial infiltration
by lymphocytes, tubular atrophy, and fibrosis.
Some patients with tubulo-interstitial nephritis
presented as distal type renal tubular acidosis.
Glomerulonephritis is a relatively rare patholog-
ical finding, and most patients have late sequelae
in the course of the disease.6 The majority of glo-
merulopathies are membranous glomerulonephri-
tis and membranoproliferative glomerulonephritis,
mainly associated with cryoglobulinemia with a
low complement 4 level. In a study by Dussol 
et al following 21 Sjögren’s syndrome patients
with glomerulonephritis,7 13 of them presented
with membranoproliferative nephritis, and six
patients presented with membranous nephropa-
thy. Cryoglobulinemia was detected in eight of
13 patients examined for cryoglobulin. ANCA-
related pauci-immune glomerulonephritis is the
most rare case, and to our knowledge, only two
cases have been reported in the English litera-
ture.8,9 Our case was an older man, with higher
creatinine levels at the initial presentation com-
pared with previous patients (Table), and he was
negative for rheumatoid factor. Other systemic
manifestations, such as pulmonary and neurolog-
ical involvement, were less than those in the other
cases. However, we could not compare the ANCA
level of each case, because of different methods
for ANCA measurement.
The combination of cyclophosphamide with
prednisolone is the standard induction therapy
for AAV-related glomerulonephritis, and we there-
fore chose this regimen for our patient. Other
immunosuppressants, such as azathioprine, me-
thotrexate, and mycophenolate mofetil, are used as
alternatives or cyclophosphamide-sparing agents.
Therapies currently under investigation are intra-
venous immunoglobulin, high-dose myeloabla-
tive chemotherapy, and various biological agents,
including tumor necrosis factor blockers, and
anti-B-cell and anti-T-cell agents.10
The renal function of most of the previous cases
of Sjögren’s syndrome complicated with rapidly
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progressive glomerulonephritis fully recovered,
but our case did not. It’s still unclear why results
differ among cases, but old age and poor initial
renal function might be involved. Since case re-
ports are rare, further information is required for
detailed analyses. A better renal recovery rate by
plasma exchange compared with intravenous
methylprednisolone (58% vs. 32%) was demon-
strated in a randomized control trial, “MEPEX”,11
in which the Cre levels of patients with AAV were
greater than 5.7 mg/dL. Therefore, the guide-
lines12 recommend plasma exchange as adjunctive
therapy for severe AAV-related acute renal failure
(Cre > 500 μmol/L). Despite the finding that there
was a lower Cre level in our patient compared with
that in the guidelines, plasma exchange might
have improved renal function of our patient.
However, his family hesitated about the use of
Table. Comparison of three patients with Sjogren’s syndrome with anti-neutrophil cytoplasmic antibody
positive crescentic glomerulonephritis
Hernandez et al8 Kamachi et al9 Our case
Age/sex 74/F 67/F 86/M
Race Spanish Japanese Taiwanese
Systemic disease Cerebrovascular accident, Chronic renal Cerebrovascular 
aortic stenosis insufficiency accident
Hemoglobin (g/dL) 8.8 5.2 9.1
BUN (mg/dL) 81 33 56
Cre (mg/dL) 2.6 2.8 4.2
Urine protein (g/day) 1.6 0.43 1.31
ANA 1,280×, speckled 320×, speckled 1,280, speckled
C3/C4 (mg/dL) normal/normal NA/NA 92/22
RF 50 U Positive Negative
p-ANCA 59 U (EIA) 603 U/mL (ELISA) > 20× (ELISA)
c-ANCA Negative Negative Negative
Anti-DNA Ab Negative NA Negative
Anti-Smith Ab Negative NA Negative
Anti-RNP Ab Negative NA Negative
Anti-Ro (U/mL) Positive 32.5 > 10
Anti-La (U/mL) Positive NA > 10
Cryoglobulin Traces Type III NA
HBV surface Ag Negative NA Negative
HCV antibodies Negative NA Negative
Renal biopsy result Sclerosed and some cellular Sclerosed glomeruli with Crescentic 
crescent glomeruli; moderate fibrocellular crescents; glomerulonephritis, 
focal infiltration by mesangial sclerosis, lymphocyte infiltration 
lymphocytes and plasma cells interstitial infiltration in the interstitial tissue
of lymphocytes
Therapy Intravenous MTP, oral Intravenous MTP, plasma Oral prednisolone, 
prednisolone exchange, oral prednisolone, cyclophosphamide 
and cyclophosphamide pulse therapy
Outcome Improved renal function Improved renal function Long-term hemodialysis
BUN = blood urea nitrogen; Cre = creatinine; ANA = antinuclear antibody; C3 = complement 3; C4 = complement 4; RF = rheumatoid
factor; p-ANCA = perinuclear anti-neutrophil cytoplasmic antibody; c-ANCA = cytoplasmic anti-neutrophil cytoplasmic antibody;
EIA = enzyme immunoassay; ELISA = enzyme-linked immunosorbent assay; NA = not applicable; HBV = hepatitis B virus; HCV = hepati-
tis C virus; MTP = methylprednisolone.
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plasma exchange with concurrent oral immuno-
suppressants, which is still the cornerstone of
treatment, and we hold this management.
In conclusion, ANCA is an uncommon autoan-
tibody detected in Sjögren’s syndrome patients as
opposed to the common autoantibodies, such as
anti-Ro and anti-La. Most of the detected ANCAs
in Sjögren’s syndrome patients are p-ANCA, pre-
dominantly anti-MPO antibody. Extra-glandular
involvement is more commonly presented in
this subgroup of patients compared with ANCA-
negative patients, but the incidence of evolvement
to ANCA-associated vasculitis is low. Nephropathy
associated with Sjögren’s syndrome is predomi-
nantly interstitial nephritis. Glomerulonephritis
is uncommon, and pauci-immune crescentic
glomerulonephritis is rare.
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